Tuberculosis (TB) remains one of the world's leading causes of death, and preventing post-treatment relapse continues to be a major global health challenge. But a new study led by scientists at the Hackensack Meridian Center for Discovery and Innovation (CDI) reveals that combining an immunotherapy with the traditional Bacille Calmette-Guérin (BCG) vaccine drastically lowers the risk of TB relapse in preclinical models.
❓ Unknown
New Strategy Combining BCG Vaccine with Immunotherapy Reduces Tuberculosis Relapse
Just now
September 17, 2026
1 min read
📰 Medical Xpress
📋 Key Takeaway
A study from the Hackensack Meridian Center for Discovery and Innovation found that combining immunotherapy with the Bacille Calmette-Guérin vaccine significantly reduces tuberculosis relapse in preclinical models. This research is crucial as tuberculosis remains a major health issue globally, including in Iran, where health challenges persist.
🏷️ Entities Mentioned
🌐
Translated from the original and edited for English readers. View original source →
Translation confidence: 100%
📰 Related Coverage
15 min ago •
Victory for Permanent Refugee Team in Mashhad Was Not Lasting / Loss in Week Five…
17 min ago •
Russia and China Block US Anti-Iran Resolution at UNSC
17 min ago •
Quantum Sensors Developed for Non-Invasive Heart Activity Detection
17 min ago •
Education Reform: The Impact of Social Media on Students in Developing Countries
18 min ago •